This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Population

Utilizing cohorts built at NYU over the last several years, this project is uniquely positioned to investigate the microbiome signatures among subjects with COPD.

Brief Title

Lung Microbiome and Inflammation in Early COPD

Official Title

Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)

Brief Summary

This is a cross sectional case controlled study to assess lung microbiome and inflammation in <br /> smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will <br /> look at active bacterial metabolic pathways in the lower airways using metagenomic and <br /> metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and <br /> host immune responses in COPD and controls. Investigators believe COPD cases will have higher <br /> prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.